

## DAFTAR PUSTAKA

- Adam, A.K., Kusumawati A., Putra R.A.N. 2018. Pengaruh Pemberian Ekstrak Etanol Daun Kemangi Sayur (*Ocimum Basilicum*) Terhadap Kadar Serum Alanin Aminotransferase (ALT) dan Aspartat Aminotransferase (AST) Mencit (*Mus musculus*) Jantan Galur Swiss yang Diinjeksi Asam Urat. 1(2):65-74.
- Apriyanto, D.R., Hartati S., Dewi B.E., Aoki-Utsubo C., Hotta H. 2018. Aktivitas Sitotoksitas Ekstrak Metanol Daun Sirsak (*Annona muricata* L.) terhadap Karsinoma Hepatoseluler Strain HUH7IT-1. *Cell Line*. 4(1):1-4.
- Artini, I.G.A., Artana I.G.N.B., Aman I.G.M., Mahendra A.N. 2017. CYP2E1 Genotype and Transaminase Level of Tuberculosis Patients Receiving Fixed Dose Combination of Antituberculosis. *Bali Medical Journal*. 3(3):S70-S74.
- Arzumanyan A., Reis H.M.G.P.V., Feitelson M.A. 2013. Pathogenic Mechanism in HBV and HCV-associated Hepatocellular Carcinoma. *Nature Review Cancer*. 13(1):123-135.
- Attwa, M.H., El-Etreby S.A. 2015. Guide for Diagnosis and Treatment of Hepatocellular Carcinoma. *World Journal of Hepatology*. 7(12):1632-1651.
- Bachofner, J.A., Valli P.V., Kroger A., Bergamin I., Kunzler P., Baserga A., *et al.* 2016. Direct Antiviral Agent Treatment of Chronic Hepatitis C Results in Rapid Regression of Transient Elastography and Fibrosis Markers Fibrosis-4 Score and Aspartate Aminotransferase Platelet Ratio Index. *Liver International*. 37(3):369-376.
- Balogh J., Victor D., Asham E.H., Burroughs S.G., Boktour M., Saharia A., *et al.* 2016. Hepatocellular Carcinoma : A Review. *Journal of Hepatocellular Carcinoma*. 3(1):41-53.
- Bambace, N.M., Holmes C.E. 2011. The Platelet Contribution to Cancer Progression. *Journal of Thrombosis and Haemostasis*. 9(2):237-249.
- Bansal S., Anandatheerthavarada H.K., Prabu G.K., Milne G.L., Martin M.V., Guengerich F.P., *et al.* 2013. Human Cytochrome P450 2E1 Mutations That Alter Mitochondrial Targeting Efficiency and Susceptibility to Ethanol-induced Toxicity in Cellular Models. *The Journal of Biological Chemistry*. 288(18):12627-12644.
- Bayomi, E.A., Barakat A.B., El-Bassuoni M.A., Talaat R.M., El-Deftar M.M., Wahab S.A.A., *et al.* 2015. Cyclooxygenase-2 Expression is Associated with Elevated Aspartate Aminotransferase Level in Hepatocellular Carcinoma. *Journal of Cancer Research and Therapeutics*. 11(4):786-792.

- Bertuccio P., Turati F., Carioli G., Rodriguez T., Vecchia C.L., Malvezzi M., *et al.* 2017. Global Trends and Predictions in Hepatocellular Mortality. *Journal of Hepatology*. 67(2):302-309.
- Bihari C., Rastogi A., Shasthry S.M., Bajpai M., Bhadoria A.S., Rajesh S., *et al.* 2016. Platelets Contribute to Growth and Metastasis in Hepatocellular Carcinoma. *Journal of Pathology, Microbiology and Immunology*. 124(9):776-786.
- Bose S., Tripathi D.M., Sukriti, Sakhuja P., Kazim S.N., Sarin S.K. 2013. Genetic Polymorphisms of CYP2E1 and DNA Repair Genes HOGG1 and XRCC1 : Association with Hepatitis B Related Advanced Liver Disease and Cancer. *Gene*. 519(2):231-237.
- Bosetti C., Turati F., Vecchia C.L. 2014. Hepatocellular Carcinoma Epidemiology. *Best Practice & Research Clinical Gastroenterology*. 28(5):753-770.
- Bota S., Piscaglia F., Marinelli S., Pecorelli A., Terzi E., Bolondi L. 2012. Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma. *Liver Cancer*. 1(1):190-200.
- Botros M., Sikaris K.A. 2013. The De Ritis Ratio: The Test of Time. *The Clinical Biochemist Reviews*. 34(3):117-130.
- Bruix J., Reig M., Morris S. 2016. Evidence-based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. *Gastroenterology*. 150(4):835-853.
- Carr, B.I., Guerra V. 2013. Thrombocytosis and Hepatocellular Carcinoma. *Digestive Diseases and Sciences*. 58(1):1790-1796.
- Catanzaro I., Naselli F., Saverini M., Giacalone A., Montalto G., Caradonna F. 2012. Cytochrome P450 2E1 Variable Number Tandem Repeat Polymorphisms and Health Risks: A Genotype-phenotype Study in Cancers Associated with Drinking and/or Smoking. *Molecular Medicine Reports*. 6(2):416-420.
- Chatterjee K., Coshic C., Borgohain M., Premchand, Thapliyal R.M., Chakroborty S., *et al.* 2012. Individual Donor Nucleic Acid Testing for Blood Safety Against HIV-1 and Hepatitis B and C Viruses in a Tertiary Care Hospital. *The National Medical Journal of India*. 25(4):207-209.
- Chedid, M.F., Kruehl C.R.P., Pinto M.A., Grezzana-Filho T.J.M., Leipnitz I., Kruehl C.D.P., *et al.* 2017. Hepatocellular Carcinoma: Diagnosis and Operative Management. *Arquivos Brasileiros de Cirurgia Digestiva*. 30(4):272-278.
- Choi J., Kim G., Han S., Lee W., Chun S., Lim Y. 2019. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. *Hepatology*. 69(5):1983-1994.

- Cornella H., Alsinet C., Villanueva A. 2011. Molecular Pathogenesis of Hepatocellular Carcinoma. *Alcoholism: Clinical and Experimental Research*. 35(5):821-825.
- Dahlan, M.S. 2014. *Statistik untuk Kedokteran dan Kesehatan: Deskriptif, Bivariat, dan Multivariat, Dilengkapi Aplikasi Menggunakan SPSS Edisi ke-6*. Epidemiologi Indonesia, Jakarta.
- Dhanasekaran R., Bandoh S., Roberts L.R. 2016. Molecular Pathogenesis of Hepatocellular Carcinoma and Impact of Therapeutic Advances. *F1000 Research*. 5(1):1-15.
- Dhanasekaran R., Limaye A., Cabrera R. 2012. Hepatocellular Carcinoma : Current Trends in Worldwide Epidemiology, Risk Factors, Diagnosis and Therapeutics. *Hepatic Medicine: Evidence and Research*. 2012(4):19-37.
- Ellingson K., Seem D., Nowicki M., Strong D.M., Kuehnert M.J. 2011. Estimated Risk of Human Immunodeficiency Virus and Hepatitis C Virus Infection Among Potential Organ Donors from 17 Organ Procurement Organizations in the United States. *American Journal of Transplantation*. 11(6):1201-1208.
- Ellis, E.L., Mann D.A. 2012. Clinical Evidence for the Regression of Liver Fibrosis. *Journal of Hepatology*. 56(5):1171-1180.
- Feng J., Pan X., Yu J., Chen Z., Xu H., El-Rifai W., *et al*. 2012. Functional PstI / RsaI Polymorphism in CYP2E1 is Associated with the Development, Progression and Poor Outcome of Gastric Cancer. *PLOS ONE*. 7(9):1-8.
- Flemming, J.A., Yang J.D., Vittinghoff E., Kim W.R., Terrault N.A. 2014. Risk Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis: The ADDRESS-HCC Risk Model. *Cancer*. 120(22):3485-3493.
- Foy, M.C., Thio C.L., Hwang H.S., Saulynas M., Hamilton J.P., Fine D.M., *et al*. 2012. False-Negative Hepatitis B Virus (HBV) Surface Antigen in a Vaccinated Dialysis Patient with a High Level of HBV DNA in the United States. *Clinical and Vaccine Immunology*. 19(5):820-822.
- Fu P., Yang F., Li B., Zhang B., Guan L., Sheng J., *et al*. 2016. Meta-analysis of CYP2E1 Polymorphisms in Liver Carcinogenesis. *Digestive and Liver Disease*. 49(1):77-83.
- Gaggini M., Cabiati M., Turco S.D., Navarra T., Simone P.D., Filipponi F., *et al*. 2017. Increased FNDC5/Irisin Expression in Human Hepatocellular Carcinoma. *Peptides*. 88(2017):62-66.
- Gao J., Wang Z., Wang G., Zhang H., Gao N., Wang J., *et al*. 2018. Higher CYP2E1 Activity Correlates with Hepatocarcinogenesis Induced by Diethylnitrosamine. *The Journal of Pharmacology and Experimental Therapeutics*. 365(2):398-407.

- Garuti F., Neri A., Avanzato F., Gramenzi A., Rampoldi D., Rucci P., *et al.* 2020. The Changing Scenario of Hepatocellular Carcinoma in Italy: an Update. *Liver International*. 1(1):1-12.
- Ghoshal U., Tripathi S., Kumar S., Mittal B., Chourasia D., Kumari N., *et al.* 2014. Genetic Polymorphism of Cytochrome P450 (CYP) 1A1, CYP1A2, and CYP2E1 Genes Modulate Susceptibility to Gastric Cancer in Patients with *Helicobacter pylori* Infection. *Gastric Cancer*. 17(1):226-234.
- Gumilas, N.S.A., Harini I.M., Ernawati D.A., Indriani V. 2019. Kajian Marka ApoAI untuk Deteksi Dini Perkembangan Sirosis Hepatis Menuju Karsinoma Hepatoseluler. *Laporan Akhir Riset Peningkatan Kompetensi*. Fakultas Kedokteran, Universitas Jenderal Soedirman, Purwokerto, 22 hal. (Tidak dipublikasikan)
- Guo Y., Xu C., Fang Y., Wang C., Gao N., Wen Q., *et al.* 2019. High CYP2E1 Activity Aggravates Hepatofibrosis by Limiting Macrophage Polarization Towards the M2 Phenotype. *Molecular Carcinogenesis*. 58(8):1481-1491.
- Hernandez-Gea V., Friedman S.L. 2011. Pathogenesis of Liver Fibrosis. *Annual Review of Pathology: Mechanisms of Disease*. 6(1):425-456.
- Hernandez-Gea V., Toffanin S., Friedman S.L., Llovet J.M. 2013. Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma. *Gastroenterology*. 144(3):512-527.
- Ioannou, G.N., Beste L.A., Green P.K., Singal A.G., Tapper E.B., Waljee A.K. 2019. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. *Gastroenterology*. 157(5):1264-1278.
- Jasirwan, C.O.M. 2018. Cedera Hati Hipoksik pada Infark Miokard Akut. *Jurnal Penyakit Dalam Indonesia*. 5(3):109.
- Jiang H., Zhang X., Shen J., Zhang Y., Gu Y., Tian T. 2019. Association Between CYP2E1 and GOT2 Gene Polymorphisms and Susceptibility and Low-dose N,N-dimethylformamide Occupational Exposure-induced Liver Injury. *Internasional Archives of Occupational and Environmental Health*. 92(1):967-975.
- Jones F., Sembiring J., Zain L.H. 2016. Akurasi Diagnostik Fibrosis Hati Berdasarkan Rasio *Red Cell Distribution Width* (RDW) dan Jumlah Trombosit Dibanding dengan Fibroscan pada Penderita Hepatitis B Kronik. *Global Medical and Health Communication*. 4(2):104-109.
- Kew, M.C. 2013. Aflatoxins as a Cause of Hepatocellular Carcinoma. *Journal of Gastrointestinal & Liver Diseases*. 22(3):305-310.
- Kew, M.C. 2014. Hepatocellular Carcinoma: Epidemiology and Risk Factors. *Journal of Hepatocellular Carcinoma*. 1(1):115-125.

- Kile, B.T. 2015. Aging Platelets Stimulate TPO Production. *Nature Medicine*. 21(1):11-12.
- Krisnansari D., Sulisyo H., KUSDARYANTO W.D. 2014. Potensi Hepatoprotektor Propolis terhadap Hepar Tikus Putih (*Rattus norvegicus*) yang Diinduksi Karbon Tetraklorida. *Jurnal Ners*. 9(2):270-278.
- Kulecka M., Wierzbicka A., Paziewska A., Mikula M., Habior A., Janczyk W., *et al.* 2017. A Heterozygous Mutation in GOT1 is Associated with Familial Macro-aspartate Aminotransferase. *Journal of Hepatology*. 67(5):1026-1030.
- Kumar, V., Aster, J.C., Abbas, A.K. 2015. *Buku Ajar Patologi Robbins Edisi ke-9*. Elsevier Saunders, Singapura.
- Lavanya V., Viswanathan V., Malar S.A.S., Malarvizhi A., Moorthy K. 2012. Prevalence of Hepatitis B Virus Infection Among Blood Donors with Antibodies to Hepatitis B Core Antigen. *International Journal of Medicine and Medical Sciences*. 4(6):128-137.
- Lee M., Yang H., Lu S., Jen C., You S., Wang L., *et al.* 2014. Hepatitis C Virus Genotype 1b Increases Cumulative Lifetime Risk of Hepatocellular Carcinoma. *International Journal of Cancer*. 135(1):1119-1126.
- Lee T., Wu J., Yu S., Lin J., Wu M., Wu C. 2017. The Occurrence of Hepatocellular Carcinoma in Different Risk Stratifications of Clinically Noncirrhotic Nonalcoholic Fatty Liver Disease. *International Journal of Cancer*. 141(7):1307-1314.
- Leung T., Rajendran R., Singh S., Garva R., Krstic-Demonacos M., Demonacos C. 2013. Cytochrome P450 2E1 (CYP2E1) Regulates the Response to Oxidative Stress and Migration of Breast Cancer Cells. *Drugs, Metabolism and Disposition*. 43(10):1450-1457.
- Li C., Li G., Miao R., Lu X., Zhong S., Sang X., *et al.* 2012. Primary Liver Cancer Presenting as Pyogenic Liver Abscess: Characteristics, Diagnosis, and Management. *Journal of Surgical Oncology*. 105(1):687-691.
- Li X., Chen Z., Xing Y., Wang T., Wu D., Wen J., *et al.* 2015. Platelet-to-lymphocyte Ratio Acts as a Prognostic Factor for Patients with Advanced Hepatocellular Carcinoma. *Tumor Biology*. 36(1):2263-2269.
- Liao R., Fu Y.P., Wang T., Deng Z.G., Li D.W., Fan J., *et al.* 2017. Metavir and FIB-4 Scores are Associated with Patient Prognosis After Curative Hepatectomy in Hepatitis B Virus Related Hepatocellular Carcinoma: A Retrospective Cohort Study at Two Centers in China. *Oncotarget*. 8(1):1774-1787.
- Liliana A., Noormartany, Sugianti A.K. 2014. Angka FIB-4 dan *Highly Active Anti Retroviral Therapy* di Antara Pasien Pengidap Infeksi HIV. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 20(2):80-84.

- Lisman T., Porte R.J. 2016. Mechanisms of Platelet-mediated Liver Regeneration. *Blood Spotlight*. 128(5):625-629.
- Liu C., Wang H., Pan C., Shen J., Liang Y. 2012. CYP2E1 PstI/RsaI Polymorphism and Interaction with Alcohol Consumption in Hepatocellular Carcinoma Susceptibility: Evidence from 1661 Cases and 2371 Controls. *Tumor Biology*. 33(1):979-984.
- Liu W., Tian F., Dai L., Chai Y. 2014. Cytochrome P450 2E1 Gene Polymorphism and Alcohol Drinking on the Risk of Hepatocellular Carcinoma: a Meta-analysis. *Molecular Biology Reports*. 41(1):7645-7650.
- Liu Z., Que S., Xu J., Peng T. 2014. Alanine Aminotransferase-Old Biomarker and New Concept: A Review. *International Journal of Medical Sciences*. 11(9):929-935.
- Lv Y., Liu C., Zhang J.F., Liu X.M., Zhang X.F. 2015. Cigarette Smoking Increases Risk of Early Morbidity After Hepatic Resection in Patients with Hepatocellular Carcinoma. *European Journal of Surgical Oncology*. 41(4):513-519.
- Mair R.D., Valenzuela A., Ha N.B., Ayoub W.S., Daugherty T., Lutchman G.A., *et al.* 2012. Incidence of Hepatocellular Carcinoma Among US Patients With Cirrhosis of Viral or Nonviral Etiologies. *Clinical Gastroenterology and Hepatology*. 10(12):1412-1417.
- Masihor, J.J.G., Mantik M.F.J., Memah M., Mongan A.E. 2013. Hubungan Jumlah Trombosit dan Jumlah Leukosit pada Pasien Anak Demam Berdarah Dengue. *Jurnal e-Biomedik (eBM)*. 1(1):391-395
- McGlynn, K.A., Petrick J.L., London W.T. 2015. Global Epidemiology of Hepatocellular Carcinoma : An Emphasis on Demographic and Regional Variability. *Clinics in Liver Disease*. 19(2):223-228.
- Mittal S., El-Serag H.B. 2013. Epidemiology of HCC : Consider the Population. *Journal of Clinical Gastroenterol*. 47(1):1-10.
- Mittal S., Kramer J.R., Omino R., Chayanupatkul M., Richardson P.A., El-Serag H.B., *et al.* 2018. Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. *Clinical Gastroenterology and Hepatology*. 16(2):252-259.
- Motino O., Frances D.E., Casanova N., Fuertes-Agudo M., Cucarella C., Flores J.M., *et al.* 2019. Protective Role of Hepatocyte Cyclooxygenase-2 Expression Against Liver Ischemia Reperfusion Injury in Mice. *Hepatology*. 70(2):650-665.
- Nadhim M., Suharti C., Hardian. 2016. Distribusi Geografis dan Tingkat Keparahan Pasien Karsinoma Hepatoseluler Etiologi Virus Hepatitis B di RS Kariadi. *Jurnal Kedokteran Diponegoro*. 5(4):1291-1302.



- Nascimento M., Piran R., DaCosta R.M., Giordani M.A., Carneiro F.S., Aguiar D.H., *et al.* 2018. Hepatic Injury Induced by Thioacetamide Causes Aortic Endothelial Dysfunction by a Cyclooxygenase Dependent Mechanism. *Life Sciences*. 212(1):168-175.
- Natsir, M.Z., Amran M., Livi H. 2019. Gambaran CT Scan atau USG Penderita Hepatoma yang Dirawat di RSUD Anutapura dan RSUD Undata Palu Periode 2015-2017. *Jurnal Medika Alkhairaat*. 1(2):61-64.
- Neuschwander-Tetri, B.A. 2017. Non-alcoholic Fatty Liver Disease. *BMC Medicine*. 15(1):45-50.
- Nilles, K.M., Caldwell S.H., Flamm S.L. 2019. Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists. *Hepatology Communications*. 3(11):1423-1434.
- Ocana S., Casas M.L., Buhigas I., Lledo J.L. 2011. Diagnostic Strategy for Occult Hepatitis B Virus Infection. *World Journal of Gastroenterology*. 17(12):1553-1557.
- Ozakyol A. 2017. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). *Journal of Gastrointestinal Cancer*. 48(1):238-240.
- Pang Q., Qu K., Zhang J., Song S., Liu S., Tai M., *et al.* 2015. The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma. *Medicine*. 94(37):1431-1441.
- Pang Q., Zhang J., Xu X., Song S., Qu K., Chen W., *et al.* 2015. Significance of Platelet Count and Platelet-based Models for Hepatocellular Carcinoma Recurrence. *World Journal of Gastroenterology*. 21(18):5607-5621.
- Park, L.S., Tate J.P., Justice A.C., Ill V.C.R., Lim J.K., Brau N., *et al.* 2011. FIB-4 Index is Associated with Hepatocellular Carcinoma Risk in HIV-Infected Patient. *Cancer Epidemiology, Biomarkers & Prevention*. 20(12):2512-2517.
- Peck-Radosavljevic M. 2017. Thrombocytopenia in Chronic Liver Disease. *Liver International*. 37(6):778-793.
- Pellicoro A., Ramachandran P., Iredale J.P. 2012. Reversibility of Liver Fibrosis. *Fibrogenesis & Tissue Repair*. 5(1):1-4.
- Permadi, A.R., Ratnawati H., Wargasetia T.L. 2016. Prevalensi dan Karakteristik Pasien Kanker Hepar di Rumah Sakit Immanuel Bandung Periode Januari 2013 hingga Desember 2014. *Journal of Medicine and Health*. 1(4):351-357.
- Perwitasari, D.A., Darmawan E., Mulyani U.A., Vlies P.V.D., Alffenaar J.C., Atthobar J., *et al.* 2018. Polymorphisms of NAT2, CYP2E1, GST and HLA Related to Drug-Induced Liver Injury in Indonesian Tuberculosis Patients. *Internasional Journal of Mycobacteriology*. 7(4):380-386.

- Petrick, J.L., Campbell P.T., Koshiol J., Thistle J.E., Andreotti G., Beane-Freeman L.E., *et al.* 2018. Tobacco, Alcohol Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. *British Journal of Cancer*. 118(1): 1005-1012.
- Promega. 2018. Technical Manual GoTaq® qPCR Master Mix Instruction for Use of Products A6001 and A6002. *Promega Corporation*, Madison.
- Promega. 2019. Technical Manual Wizard® Genomic DNA Purification Kit Instruction for Use of Products A1120, A1123, A1125 and A1620. *Promega Corporation*, Madison.
- Rasyada A., Nasrul E., Edward Z. 2014. Hubungan Nilai Hematokrit Terhadap Jumlah Trombosit pada Penderita Demam Berdarah Dengue. *Jurnal Kesehatan Andalas*. 3(3):343-347.
- Reeves H.L., Zaki M.Y.W., Day C.P. 2016. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. *Digestive Diseases and Sciences*. 61(1):1234-1245.
- Rohani E., Hernaningsih Y., Ma'at S., Maimunah U. 2013. *Immature Platelet Fraction (IPF) dan Trombopoietin di Sirosis Hati*. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 19(2):112-118.
- Rosida A. 2016. Pemeriksaan Laboratorium Penyakit Hati. *Berkala Kedokteran*. 12(1):123-131.
- Safithri F. 2018. Mekanisme Regenerasi Hati secara Endogen pada Fibrosis Hati. *Jurnal Berkala Ilmiah Kedokteran dan Kesehatan*. 2(4):9-26.
- Sameer, A.S., Nissar S., Qodri Q., Alam S., Baba S.M., Siddiqi M.A. 2011. Role of CYP2E1 Genotypes in Susceptibility to Colorectal Cancer in the Kashmiri Population. *Human Genomics*. 5(6):530-537.
- Santi V., Buccione D., Micoli A.D., Fatti G., Frigerio M., Farinati F., *et al.* 2012. The Changing Scenario of Hepatocellular Carcinoma Over the Last Two Decades in Italy. *Journal of Hepatology*. 56(2):397-405.
- Sastroasmoro S., Ismael S. 2014. *Dasar-dasar Metodologi Penelitian Klinis Edisi ke-5*. Sagung Seto, Jakarta.
- Sebastiani G., Gkouvatsos K., Plebani M. 2011. Non-invasive Assessment of Liver Fibrosis: It is Time for Laboratory Medicine. *Clinical Chemistry and Laboratory Medicine*. 49(1):13-32.
- Shah, M.B., Wilderman P.R., Pascual J., Zhang Q., Stout C.D., Halpert J.R. 2012. Conformational Adaption of Human Cytochrome P450 2B6 and Rabbit Cytochrome P450 2B4 Revealed upon Binding Multiple Amlodipine Molecules. *Biochemistry*. 51(37):7225-7238.



- Shi L., Feng Y., Lin H., Ma R., Cai X. 2014. Role of Estrogen in Hepatocellular Carcinoma: is Inflammation the Key?. *Journal of Translational Medicine*. 93(2014):1-9.
- Siddiqui, M.S., Sterling R.K., Luketic V.A., Puri P., Stravitz R.T., Bouneva I., *et al.* 2013. Association Between High-Normal Levels of Alanine Aminotransferase and Risk Factors for Atherogenesis. *Gastroenterology*. 145(6):1271-1279
- Sidharthan S., Kottilil S. 2014. Mechanisms of Alcohol-induced Hepatocellular Carcinoma. *Hepatology International*. 8(1):452-457.
- Sinaga, N.P.M., Susilaningsih N. 2019. Pengaruh Pemberian Ekstrak Daun Sirsak Terhadap Derajat Histopatologi pada Tikus Wistar Karsinoma Hepatoseluler yang Mendapat Terapi Standar Sorafenib. *Jurnal Kedokteran Diponegoro*. 8(4):1197-1209.
- Singal, A.G., Pillai A., Tiro J. 2014. Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis. *PLOS Medicine*. 11(4):1-20.
- Singh, A.K., Kumar R., Pandey A.K. 2018. Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers. *Current Chemical Genomics and Translational Medicine*. 12(1):9-26.
- Siregar, G.A. 2011. Penatalaksanaan Non Bedah dari Karsinoma Hati. *Universa Medicina*. 24(1):35-42.
- Sookoian S., Pirola C.J. 2012. Alanine and Aspartate Aminotransferase and Glutamine Cycling Pathway: Their Roles in Pathogenesis of Metabolic Syndrome. *World Journal of Gastroenterology*. 18(29):3775-3781.
- Subramaniam S., Kelley R.K., Venook A.P. 2013. A Review of Hepatocellular Carcinoma (HCC) Staging Systems. *Chinese Clinical Oncology*. 2(4):33-44.
- Suh B., Park S., Shin D.W., Yun J. M., Yang H.K., Yu S.J., *et al.* 2015. High Liver Fibrosis Indeks FIB-4 is Highly Predictive of Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. *Hepatology*. 61(4):1261-1268.
- Suh B., Yun J.M., Park S., Shin D.W., Lee T.H., Yang H., *et al.* 2015. Prediction of Future Hepatocellular Carcinoma Incidence in Moderate to Heavy Alcohol Drinkers with the FIB-4 Liver Fibrosis Index. *Cancer*. 121(21):3818-3825.
- Tajiri K., Shimizu Y. 2013. Liver Physiology and Liver Diseases in the Elderly. *World Journal of Gastroenterology*. 19(46):8459-8467.
- Taylor A., Munro A., Allen E., Dunleavy K., Cameron S., Miller L., *et al.* 2013. Low Incidence of Hepatitis C Virus Among Prisoners in Scotland. *Addiction*. 108(7):1296-1304.

- Tian Z., Li Y.L., Zhao L., Zhang C.L. 2012. CYP2E1 RsaI/PstI Polymorphism and Liver Cancer Risk among East Asians : a Huge Review and Meta-analysis. *Asian Pacific Journal of Cancer Prevention*. 13(10):4915-4921.
- Tokushige K., Hashimoto E., Horie Y., Taniai M., Higuchi S. 2011. Hepatocellular Carcinoma in Japanese Patients with Non Alcoholic Fatty Liver Disease, Alcoholic Liver Disease, and Chronic Liver Disease of Unknown Etiology: Report of The Nationwide Survey. *Journal Gastroenterol*. 46(1):1230-1237.
- Toney, M.D. 2013. Aspartate Aminotransferase: An Old Dog Teaches New Tricks. *Archives of Biochemistry and Biophysics*. 544(1):119-127.
- Toyoda H., Kumada T., Tada T., Kaneoka Y., Maeda A. 2015. A Laboratory Marker, FIB-4 Index, as a Predictor for Long-term Outcomes of Hepatocellular Carcinoma Patients After Curative Hepatic Resection. *Surgery*. 157(4):699-707.
- Tseng T., Liu C., Su T., Yang W., Chen C., Yang H., *et al*. 2017. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. *American Journal of Gastroenterology*. 112(10):1564-1574.
- Turati F., Talamini R., Pelucchi C., Polesel J., Franceschi S., Crispo A. 2013. Metabolic Syndrome and Hepatocellular Carcinoma Risk. *British Journal of Cancer*. 108(1):222-228.
- Tzartzeva K., Obi J., Rich N.E., Parikh N.D., Marrero J.A., Yopp A., *et al*. 2018. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. *Gastroenterology*. 154(6):1706-1718.
- Wahyuni, R.D. 2016. Analisis Derajat Fibrosis Hati dengan *Fibroscan*, Indeks FIB4, *King's Score*, dan *APRI Score* pada Penyakit Hepatitis Kronis. *Jurnal Kesehatan Tadulako*. 2(2):42-52.
- Waller, L.P., Deshpande V., Pyrsopoulos N. 2015. Hepatocellular Carcinoma : A Comprehensive Review. *World Journal of Hepatology*. 7(26):2648-2663.
- Wang C., Wang X., Gong G., Ben Q., Qiu W., Chen Y., *et al*. 2012. Increased Risk of Hepatocellular Carcinoma in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis of Cohort Studies. *International Journal of Cancer*. 130(7):1639-1648.
- Wang Q., Luan W., Villanueva G.A., Rahbari N.N., Yee H.T., Mannizate F., *et al*. 2012. Clinical Prognostic Variables in Young Patients (Under 40 Years) with Hepatitis B Virus Associated Hepatocellular Carcinoma. *Journal of Digestive Diseases*. 13(1):214-218.
- Wira, Lopa A.T., Samad I.A. 2016. Analisis *King's Score* di Penyakit Hati Kronis Berdasarkan *Fibroscan*. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 22(2):163-167.

- Wong, M.C.S., Huang J.L.W., George J., Huang J., Leung C., Eslam M., *et al.* 2019. The Changing Epidemiology of Liver Diseases in the Asia-Pacific Region. *Nature Reviews Gastroenterology & Hepatology*. 16(1):57-73.
- World Health Organization. 2020. *Hepatitis C* (online). <https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c> diakses 10 Agustus 2020.
- Wrenger C., Muller I.B., Schifferdecker A.J., Jain R., Jordanova R., Groves M.R. 2011. Specific Inhibition of the Aspartate Aminotransferase of *Plasmodium falciparum*. *Journal of Molecular Biology*. 405(4):956-971.
- Xu J., Ma H., Liang S., Sun M., Karin G., Koyama Y., *et al.* 2017. The Role of Human Cytochrome P450 2E1 in Liver Inflammation and Fibrosis. *Hepatology Communications*. 1(10):1043-1057.
- Xu Z., Ma J., Qu C., Hu Y., Hao B., Sun Y., *et al.* 2017. Identification and Expression Analyses of the Alanine Aminotransferase (AlaAT) Gene Family in Poplar Seedlings. *Scientific Report*. 45933(2017):1-13.
- Yang D., Hanna D.L., Usher J., LoCoco J., Chaudhari P., Lenz H.J., *et al.* 2014. Impact of Sex on the Survival of Patients With Hepatocellular Carcinoma: A Surveillance, Epidemiology, and End Result Analysis. *Cancer*. 120(3):3707-3716.
- Ye X., Wang X., Shang L., Zhu G., Su H., Han C., *et al.* 2018. Genetic Variants of ALDH2-rs671 and CYP2E1-rs2031920 Contributed to Risk of Hepatocellular Carcinoma Susceptibility in a Chinese Population. *Cancer Management and Research*. 2018(10):1037-1050.
- Yip, T.C., Chan H.L., Wong V.W., Tse Y., Lam K.L., Wong G.L. 2017. Impact of Age and Gender on Risk of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance. *Journal of Hepatology*. 67(5):902-908.
- Yulia D. 2019. Virus Hepatitis B Ditinjau dari Aspek Laboratorium. *Jurnal Kesehatan Andalas*. 8(4):247-254.
- Yulianti Y., Rachmawati B. 2016. RDW, Jumlah Trombosit dan RPR dengan Indeks FIB-4 di Hepatitis C. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 22(2):147-150.
- Zamor, P.J., deLemos A.S., Russo M.W. 2017. Viral Hepatitis and Hepatocellular Carcinoma: Etiology and Management. *Journal of Gastrointestinal Oncology*. 8(2):229-242.
- Zhang Y., Wang R., Yang X. 2018. FIB-4 Index Serves as a Noninvasive Prognostic Biomarker in Patients with Hepatocellular Carcinoma: A Meta-analysis. *Medicine (Baltimore)*. 97(51):1-7.

- Zhou J., Wen Q., Li S., Zhang Y., Gao N., Tian X., *et al.* 2016. Significant Change of Cytochrome P450s Activities in Patients with Hepatocellular Carcinoma. *Oncotarget*. 7(31):50612-50623.
- Zhu J., Lin Z., Wu J., Yin H., Dai J., Feng Z., *et al.* 2014. Analysis of Serum Haptoglobin Fucosylation in Hepatocellular Carcinoma and Liver Cirrhosis of Different Etiologies. *Journal of Proteome Research*. 13(1):2986-2997.
- Zhu, R.X, Seto W., Lai C., Yuen M. 2016. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. *Gut and Liver*. 10(3):332-339.
- Zucman-Rossi J., Villanueva A., Nault J., Llovet J.M. 2015. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. *Gastroenterology*. 149(5):1226-1239.

